1-(tert-butyl)-4-(methoxymethoxy)benzene | 271600-96-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(tert-butyl)-4-(methoxymethoxy)benzene
• 英文别名: 1-tert-butyl-4-(methoxymethoxy)benzene
• CAS: 271600-96-5
• 化学式: C₁₂H₁₈O₂
• 分子量: 194.274
• InChiKey: KOUFOLRRYLERAE-UHFFFAOYSA-N

物化性质

• 沸点：
  264.0±33.0 °C(Predicted)
• 密度：
  0.957±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(tert-butyl)-4-(methoxymethoxy)benzene 在 bismuth(III) chloride 作用下， 以 水 、 乙腈 为溶剂， 反应 1.0h， 以86%的产率得到4-叔丁基苯酚
  参考文献：
  名称：

  三氯化铋介导的酚甲氧基甲基醚裂解

  摘要：

  摘要描述了一种在乙腈/水中 30 mol% 三氯化铋存在下去除酚类甲氧基甲基醚的简单有效方法。裂解方案的显着特点需要使用环保型铋试剂、易于处理、成本低、操作简单和良好的官能团兼容性。许多结构不同的酚类甲氧基甲基醚以良好到极好的产率裂解。图形概要

  DOI：

  10.1080/00397911.2016.1158270
• 作为产物：
  描述：

  4-叔丁基苯酚 、 氯甲基甲基醚 在 sodium hydride 作用下， 以 四氢呋喃 、 mineral oil 为溶剂， 反应 12.0h， 以58%的产率得到1-(tert-butyl)-4-(methoxymethoxy)benzene
  参考文献：
  名称：

  手性含氟Fe（III）Salen配合物对孤立的碳-碳双键的前所未有的不对称环氧化作用：开发亲脂性的催化剂设计。

  摘要：

  描述了以Fe（III）为中心的手性salen配合物对孤立的碳-碳双键的首次不对称环氧化。这是利用荧光标记的分子内亲氟作用的新型新颖不对称空间结构催化剂的第一个实例。

  DOI：

  10.1002/ejoc.201900146

文献信息

• NOVEL 3-(4(BENZYLOXY)PHENYL)HEX-4-INOIC ACID DERIVATIVE, METHOD OF PREPARING SAME AND PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING METABOLIC DISEASE INCLUDING SAME AS EFFECTIVE INGREDIENT
  申请人：HYUNDAI PHARM CO., LTD

  公开号：US20160024063A1

  公开（公告）日：2016-01-28

  The present invention relates to a novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative, a preparation method thereof, and a pharmaceutical composition comprising the same as an active ingredient for the prevention and treatment of metabolic disease. The novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention has excellent activities of activating GPR40 protein and promoting insulin secretion accordingly but has no toxicity when co-administered with other drugs. That is, the novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention can be co-administered with other drugs and can promote the activation of GPR40 protein significantly, so that the composition comprising the same as an active ingredient can be efficiently used as a pharmaceutical composition for the prevention and treatment of metabolic disease such as obesity, type I diabetes, type II diabetes, incompatible glucose tolerance, insulin resistance, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia, and syndrome X, etc.

  本发明涉及一种新型的3-(4-(苄氧基)苯基)己-4-羧酸衍生物，其制备方法以及包含该衍生物作为活性成分的药物组合物，用于预防和治疗代谢性疾病。本发明的这种新型的3-(4-(苄氧基)苯基)己-4-羧酸衍生物、其光学异构体或其药用可接受盐，对于激活GPR40蛋白并相应地促进胰岛素分泌具有优良活性，且在与其他药物联合使用时没有毒性。也就是说，本发明的这种新型的3-(4-(苄氧基)苯基)己-4-羧酸衍生物、其光学异构体或其药用可接受盐，可以与其他药物联合使用，并且能显著促进GPR40蛋白的激活，使得包含其作为活性成分的组合物能有效地用作预防和治疗诸如肥胖、I型糖尿病、II型糖尿病、糖耐量异常、胰岛素抵抗、高血糖、高脂血症、高甘油三酯血症、高胆固醇血症、血脂异常和X综合症等代谢性疾病的药物组合物。
• HETEROARYL DERIVATIVES AND USES THEREOF
  申请人：Jacobus Pharmaceutical Company, Inc.

  公开号：US20140135320A1

  公开（公告）日：2014-05-15

  The present invention relates to antimalarial compounds and their use against protozoa of the genus Plasmodium , including drug-resistant Plasmodia strains. This invention further relates to compositions containing such compounds and a process for making the compounds.

  本发明涉及抗疟疾化合物及其用于对抗疟原虫属Plasmodium的使用，包括对抗药物耐药Plasmodia菌株的使用。本发明还涉及含有这种化合物的组合物以及制备这些化合物的方法。
• MODULATORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE
  申请人：Durand-Reville Thomas

  公开号：US20110021513A1

  公开（公告）日：2011-01-27

  The present invention relates to modulators of IRAK kinase and provides compositions comprising such modulators, as well as methods therewith for treating conditions or diseases mediated by or associated with IRAK kinase.

  本发明涉及IRAK激酶的调节剂，并提供包含这些调节剂的组合物，以及利用这些调节剂治疗由IRAK激酶介导或相关的疾病或病症的方法。
• DIPHENYL SULFIDE DERIVATIVES AND MEDICINES CONTAINING SAME AS ACTIVE INGREDIENT
  申请人：Kohno Yasushi

  公开号：US20120101068A1

  公开（公告）日：2012-04-26

  Provided are diphenyl sulfide derivatives which have excellent S1P3 antagonistic activity and are useful as drugs. Intensive studies have been made for the purpose of creating a compound having S1P3 antagonistic activity. As a result of the intensive studies, it has been found that diphenyl sulfide derivatives represented by general formula (1) have excellent S1P3 antagonistic activity. In general formula (1), R 1 is a hydrogen atom or the like; R 2 is an optionally substituted alkyl group having 1 to 6 carbon atoms, or the like; X is a methylene group which may be substituted with one or two fluorine atoms, or the like; Y is a hydrogen atom or the like; and Z is a halogen atom.

  提供了具有优异S1P3拮抗活性并且可用作药物的二苯基硫醚衍生物。为了创造具有S1P3拮抗活性的化合物，进行了深入研究。经过深入研究，发现由通式（1）表示的二苯基硫醚衍生物具有优异的S1P3拮抗活性。在通式（1）中，R1是氢原子或类似物；R2是具有1至6个碳原子的可选择取代的烷基基团或类似物；X是一个甲基基团，可能被一个或两个氟原子取代，或类似物；Y是氢原子或类似物；Z是卤素原子。
• Complexes of phosphine–phenolate ligands with the [ReO]3+ and [Re(HNNC5H4N)(NNC5H4N)]2+ cores
  作者：Michael S. Kovacs、Peter Hein、Sherwin Sattarzadeh、Brian O. Patrick、Thomas J. Emge、Chris Orvig

  DOI：10.1039/b104274m

  日期：2001.10.11

  Complexes incorporating the [ReO]3+ core have been synthesised with ligands containing the new methyl substituted phosphine–phenolate PO and PO2 donor sets, (2-hydroxy-5-methylphenyl)diphenylphosphine (H(MePO)) and bis(2-hydroxy-5-methylphenyl)phenylphosphine (H2(Me2PO2)). The analogous tert-butyl ligands, (5-tert-butyl-2-hydroxyphenyl)diphenylphosphine (H(t-BuPO)) and bis(5-tert-butyl-2-hydroxyphenyl)phenylphosphine (H2(t-Bu2PO2)), were also prepared. Reaction of either mer-[ReOCl3(PPh3)2] or [NH4][ReO4] in CH3OH with H(MePO) led to formation of [ReOCl(MePO)2] (1) in good yield. Reaction of [NH4][ReO4] with H2(Me2PO2) in CH3OH afforded [ReO(Me2PO2)(H(Me2PO2))] (2), also in good yield. X-Ray crystallographic analyses of 1 and 2 demonstrated that both complexes are neutral and octahedral, and contain the oxo moiety. Two complexes have been structurally characterised from the reaction of (o-hydroxyphenyl)diphenylphosphine (HPO) with [Re(Hhypy)(hypyH)Cl3]: [Re(Hhypy)(hypy)(PO)(HPO)]Cl (3) and [ReCl(Hypy)(hypy)(PO)] (4) (hypy = NNC5H4N, Hhypy = HNNC5H4N, hypyH = NNC5H4NH). X-Ray crystallography demonstrated that both are Re(III) complexes; 3 is monocationic with an N3OP2 coordination sphere while 4 is neutral with a ClN3OP coordination sphere. [Re(Hhypy)(hypy)(HPO2)(H2PO2)]Cl (5) and [Re(Hhypy)(hypy)(H(Me2PO2))(H2(Me2PO2))]Cl (6) were synthesised by reaction of [Re(Hhypy)(hypyH)Cl3] in CH3OH with bis(o-hydroxyphenyl)phenylphosphine (H2PO2) and H2(Me2PO2) respectively. Compounds 5 and 6 were shown by 1H and 31P NMR spectroscopies to have the same N3OP2 coordination sphere as [Re(Hhypy)(hypy)(PO)(HPO)]Cl, with the addition of several uncoordinated, protonated phenolic donors.

  合成了包含 [ReO]3+ 核心的配合物，使用了含有新甲基取代膦-酚类 PO 和 PO2 供体组的配体，包括 (2-hydroxy-5-methylphenyl)diphenylphosphine (H(MePO)) 和 bis(2-hydroxy-5-methylphenyl)phenylphosphine (H2(Me2PO2))。类似的叔丁基配体，也准备了 (5-tert-butyl-2-hydroxyphenyl)diphenylphosphine (H(t-BuPO)) 和 bis(5-tert-butyl-2-hydroxyphenyl)phenylphosphine (H2(t-Bu2PO2))。在 CH3OH 中用 H(MePO) 反应 mer-[ReOCl3(PPh3)2] 或 [NH4][ReO4] 可以良好地产生 [ReOCl(MePO)2] (1)。用 H2(Me2PO2) 处理 [NH4][ReO4] 也能在 CH3OH 中很好的得到 [ReO(Me2PO2)(H(Me2PO2))] (2)。对 1 和 2 的 X 射线晶体学分析表明，这两个配合物都是中性的八面体结构，并包含氧基。通过 (o-hydroxyphenyl)diphenylphosphine (HPO) 与 [Re(Hhypy)(hypyH)Cl3] 的反应，两个配合物被结构上表征为：[Re(Hhypy)(hypy)(PO)(HPO)]Cl (3) 和 [ReCl(Hypy)(hypy)(PO)] (4)（hypy = NNC5H4N，Hhypy = HNNC5H4N，hypyH = NNC5H4NH）。X 射线晶体学表明，两个都是 Re(III) 配合物；3 为单阳离子，具有 N3OP2 配位环境，而 4 是中性的，具有 ClN3OP 配位环境。通过在 CH3OH 中将 [Re(Hhypy)(hypyH)Cl3] 与 bis(o-hydroxyphenyl)phenylphosphine (H2PO2) 和 H2(Me2PO2) 反应合成了 [Re(Hhypy)(hypy)(HPO2)(H2PO2)]Cl (5) 和 [Re(Hhypy)(hypy)(H(Me2PO2))(H2(Me2PO2))]Cl (6)。通过 1H 和 31P NMR 光谱分析证明，化合物 5 和 6 具有与 [Re(Hhypy)(hypy)(PO)(HPO)]Cl 相同的 N3OP2 配位环境，并增加了一些未配位的质子化酚类供体。